MEXICO CITY , July 24, 2024 /PRNewswire/ -- M8 Pharmaceuticals, an Acino company ("M8"), today announces the signature of an exclusive licensing and distribution agreement with LG Chem Ltd., a global company headquartered in South Korea that specializes in life sciences as one of its core businesses, to market, commercialize, and distribute Hyruan One ® in Brazil , and Zemiglo ® and Zemimet ® SR (Zemiduo ® SR in Mexico ) in Mexico , Central America , and the Dominican Republic . Gemigliptin, sold under the brand names Zemiglo ® and Zemimet ® SR (Zemiduo ® SR in Mexico ), is a reversible, potent, selective, competitive, and long-acting inhibitor of dipeptidyl peptidase (DPP)-4, for use as monotherapy or in combination with metformin or sulfonylureas (SU) to treat hyperglycemia in patients with Type 2 diabetes.
The once-daily Zemimet ® SR (Zemiduo ® SR in Mexico ) is currently the number one brand in the Type 2 diabetes market in South Korea . Hyruan One ® is a single-injection treatment of hyaluronic acid (HA), also known as sodium hyaluronate, to replace diseased synovial fluid and restore the loss of viscoelasticity in joints caused by osteoarthritis (OA). Formulated with cutting-edge technology, Hyruan One ® is a biofermented, cross-linked HA injection indicated for the treatment of OA of the knee.
This strategic partnership aligns with Acino's mission to provide the people of Latin America with improved access to innovative medicines, strengthening M8's presence.